Paola Betancur

Has grant

Assistant Professor

University of California, San Francisco
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Paola Betancur is an Assistant Professor at the University of California San Francisco, USA. Her research areas focus on cancer biology, particularly the mechanisms of overexpression and therapy resistance, as well as the role of certain gene activations in the immune response. Recently, she has contributed to studies investigating enhancer clusters in cancer and the relationship between super-enhancers and prognosis in breast cancer.

Recent Grants

Grant: Close

Identification of Novel Gene Regulatory Interactions Driving the Immune Evasion Program Through Transcriptional Activation of CD47 in Cancer

Open Date: 2019-09-01

Close Date: 2022-08-01

Articles (4)

Despite efforts to understand breast cancer biology, metastatic disease remains a clinical challenge. Identifying suppressors of breast cancer progression and mechanisms of transition to more invasive phenotypes could provide game changing therapeutic opportunities. Transcriptional deregulation is central to all malignancies, highlighted by the extensive reprogramming of regulatory elements that underlie oncogenic programs. Among these, super-enhancers (SEs) stand out due to their enrichment in genes controlling cancer hallmarks. To reveal novel breast cancer dependencies, we integrated the analysis of the SE landscape with master regulator activity inference for a series of breast cancer cell lines. As a result, we identified T - h elper-inducing Poxviruses and Zinc-finger ( PO Z)/ K rüppel-like factor (ThPOK, ZBTB7B ), a CD4 + cell lineage commitment factor, as a breast cancer master regulator that is recurrently associated with a SE. ThPOK expression is highest in luminal breast cancer but is significantly reduced in the basal subtype. Manipulation of ThPOK levels in cell lines shows that its repressive function restricts breast cancer cells to an epithelial phenotype by suppressing the expression of genes involved in the epithelial-mesenchymal transition (EMT), WNT/β-catenin target genes, and the pro-metastatic TGFβ pathway. Our study reveals ThPOK as a master transcription factor that restricts the acquisition of metastatic features in breast cancer cells.

Year:

2024

Year:

2023

Year:

2022

Year:

2020

Collaborators (4)

Mary Helen Barcellos-Hoff

Professor/Vice Chair

University of California, San Francisco

UNITED STATES
View details

Laura J. van 't Veer

University of California, San Francisco

UNITED STATES
View details

Rosalyn Sayaman

Assistant Adjunct Professor

University of California, San Francisco

UNITED STATES
View details

Julie Saba

Professor

University of California, San Francisco

UNITED STATES
View details